Tarlatamab Biosimilar – Anti-DLL3;CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA1720; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tarlatamab Biosimilar, also known as Anti-DLL3,CD3E mAb, is a monoclonal antibody that has been developed as a biosimilar to the existing drug, Tarlatamab. This biosimilar is designed to target and bind to the DLL3 protein, which is overexpressed in various types of cancer, making it a potential therapeutic option for cancer treatment.
Tarlatamab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, and is produced through genetic engineering techniques using mammalian cell lines. The antibody has a specific binding site on its variable region, which allows it to bind to the DLL3 protein.
Tarlatamab Biosimilar works by binding to the DLL3 protein, which is a Notch ligand that is highly expressed in various types of cancer, including small cell lung cancer (SCLC), neuroendocrine tumors, and others. DLL3 plays a crucial role in cancer cell proliferation, survival, and invasion, making it a promising therapeutic target. By binding to DLL3, Tarlatamab Biosimilar inhibits the Notch signaling pathway, which is essential for cancer cell growth and survival. This leads to the inhibition of tumor growth and ultimately, cancer cell death.
Tarlatamab Biosimilar is currently being studied for its potential use in the treatment of various types of cancer, including SCLC, neuroendocrine tumors, and other DLL3-expressing cancers. It is being evaluated as a monotherapy as well as in combination with other cancer treatments, such as chemotherapy and immunotherapy. This biosimilar has shown promising results in preclinical studies and is currently in phase I clinical trials for the treatment of SCLC.
As a biosimilar, Tarlatamab Biosimilar offers several advantages over the existing drug, Tarlatamab. Firstly, being a biosimilar, it has a similar structure and mechanism of action as the original drug, making it a potential alternative for patients who may not respond to Tarlatamab or may experience adverse effects. Additionally, being a recombinant antibody, it has a lower risk of immunogenicity and can be produced in large quantities, making it more cost-effective.
In conclusion, Tarlatamab Biosimilar is a promising therapeutic option for the treatment of various types of cancer, especially those that overexpress the DLL3 protein. Its unique mechanism of action and advantages as a biosimilar make it a potential alternative for cancer patients. Further studies and clinical trials are needed to fully evaluate its efficacy and safety, but it holds great potential in the fight against cancer.
ProteoGenix catalogue number PX-TA1720. For research use only.
Target: Tarlatamab Biosimilar – Anti-DLL3;CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tarlatamab Biosimilar – Anti-DLL3;CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
